ADC’s loncastuximab data could clear path for BLA, IPO filing

B cell lymphoma data give ADC Therapeutics dry powder as it prepares to mount a second IPO attempt

Months after scuttling a planned listing, ADC Therapeutics intends to refile for an IPO as it prepares to submit a BLA in 3Q19 seeking accelerated approval for its antibody-drug conjugate to treat DLBCL in a third-line setting.

The company said Thursday that loncastuximab tesirine (ADCT-402) led to an overall

Read the full 485 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE